Taurine 8 pp 371-394 | Cite as

Comparative Evaluation of Taurine and Thiotaurine as Protectants Against Diabetes-Induced Nephropathy in a Rat Model

  • Kashyap G. Pandya
  • Roshil Budhram
  • George Clark
  • Cesar A. Lau-CamEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 775)


Taking into account the proven effectiveness of antioxidants in preventing experimentally induced diabetes in laboratory animals, this study was carried out with the specific purpose of comparing the effectiveness of two known antioxidants, the β-aminosulfonate taurine (TAU) and β-aminothiosulfonate thiotaurine (TTAU), in preventing biochemical, functional and histological alterations indicative of ­diabetic nephropathy. In the study, streptozotocin (60 mg/kg, orally) was used to induce type 2 diabetes mellitus in Sprague-Dawley rats. Starting on day 15 and continuing up to day 56, the rats received a daily single 2.4 mmol/kg oral dose of a sulfur-containing compound (TAU or TTAU) or 4 U/kg subcutaneous dose of isophane insulin (INS). Rats not receiving any treatment served as controls. After obtaining a 24 h urine sample, the animals were sacrificed by decapitation on day 57, and their blood and kidneys immediately collected. Diabetic rats exhibited marked hyperglycemia, hypoinsulinemia, hypoproteinemia, hyponatremia, hyperkalemia, azotemia, hypercreatinemia, increased plasma TGF β1, lipid peroxidation, plasma and kidney nitrite, and urine output; decreased glutathione redox status in plasma and kidney, decreased urine Na+ and K+, proteinuria and hypocreatinuria. Without exceptions, all the treatment compounds were found to markedly and variously attenuate these changes. Confirmation of protection by INS, TAU and TTAU was provided by the results of histological examination of kidney sections and which showed a more normal appearance than sections from diabetic animals. In most instances protection by TTAU was about equal to that by INS but greater than that by TAU.


Mesangial Expansion Treatment Compound Nonenzymatic Glycation Isophane Insulin Blood HbA1c 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.













Glycosylated hemoglobin


Transforming growth factor-β1


Blood urea nitrogen








Total protein




Reduced glutathione


Glutathione disulfide


  1. Acharya M, Lau-Cam CA (2010) Comparison of the protective actions of N-acetylcysteine, hypotaurine and taurine against acetaminophen-induced hepatotoxicity in the rat. J Biomed Sci 17:S35PubMedCrossRefGoogle Scholar
  2. Adler S (2004) Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int 66:2095–2106PubMedCrossRefGoogle Scholar
  3. Aruoma OI, Halliwell B, Hoey BM, Butler J (1988) The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 256:251–255PubMedGoogle Scholar
  4. Arya A, Aggarwal S, Yadav HN (2010) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2:24–29Google Scholar
  5. Balakumar P, Chakkarwar VA, Kumar V, Jain A, Reddy J, Singh M (2008) Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 9:189–195PubMedCrossRefGoogle Scholar
  6. Balkan J, Doğru-Abbasoğlu S, Kanbağli O, Cevikbaş U, Aykaç-Toker G, Uysal M (2001) Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 20:251–254PubMedCrossRefGoogle Scholar
  7. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 293:471–474CrossRefGoogle Scholar
  8. Brøns C, Spohr C, Storgaard H, Dyerberg J, Vaag A (2004) Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur J Clin Nutr 58:1239–1247PubMedCrossRefGoogle Scholar
  9. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302–310PubMedCrossRefGoogle Scholar
  10. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER (2002) Glucose-induced oxidative stress in mesangial cells. Kidney Int 61:599–608PubMedCrossRefGoogle Scholar
  11. Cavallini D, De Marco C, Mondovi B (1960) Enzymatic conversion of cystamine into thiotaurine. Boll Soc Ital Biol Sper 36:1915–1918PubMedGoogle Scholar
  12. Cavallinid D, De Marco C, Mondovi B (1959) Chromatographic evidence on the occurrence of thiotaurine in the urine of rats fed with cystine. Biol Chem 234:854–857Google Scholar
  13. Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK (1997) Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-beta, and glomerular size in diabetes. J Am Soc Nephrol 8:1405–1414PubMedGoogle Scholar
  14. Das J, Sil PC (2012) Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids 43:1509–1523Google Scholar
  15. Derlacz RA, Sliwinska M, Piekutowska A, Winiarska K, Drozak J, Bryla J (2007) Melatonin is more effective than taurine and 5-hydroxytryptophan against hyperglycemia-induced kidney-cortex tubules injury. J Pineal Res 42:203–209PubMedCrossRefGoogle Scholar
  16. Doerr RC, Fox JB, Lakritz L, Fiddler W (1981) Determination of nitrite in cured meats by chemiluminescence. Anal Chem 53:381–384CrossRefGoogle Scholar
  17. Egawa M, Kohno Y, Kumano Y (1999) Oxidative effects of cigarette smoke on the human skin. Int J Cosmet Sci 21:83–98PubMedCrossRefGoogle Scholar
  18. Fares J, Kanaan M, Chaaya M, Azar S (2010) Fluctuations in glycosylated hemoglobin (HbA1c) as a predictor for the development of diabetic nephropathy in type 1 diabetic patients. Int J Diabetes Mellitus 2:10–14CrossRefGoogle Scholar
  19. Fellman JH, Green TR, Eicher AL (1987) The oxidation of hypotaurine to taurine: bis-aminoethyl-α-disulfone, a metabolic intermediate in mammalian tissue. Adv Exp Med Biol 217:39–48PubMedGoogle Scholar
  20. Flyvbjerg A (2000) Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205–1223PubMedCrossRefGoogle Scholar
  21. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090–3094PubMedCrossRefGoogle Scholar
  22. Franconi F, Di Leo MA, Bennardini F, Ghirlanda G (2004) Is taurine beneficial in reducing risk factors of diabetes? Neurochem Res 29:143–150PubMedCrossRefGoogle Scholar
  23. Goldfarb S, Ziyadeh FN (2001) TGF-β: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 112:27–33PubMedGoogle Scholar
  24. Green TR, Fellman JH, Eicher AL, Pratt KL (1991) Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. Biochim Biophys Acta 1073:91–97PubMedCrossRefGoogle Scholar
  25. Güntherberg H, Rost J (1966) The true oxidized glutathione content of red blood cells obtained by new enzymic and paper chromatographic methods. Anal Biochem 15:205–210PubMedCrossRefGoogle Scholar
  26. Ha H, Kim KH (1999) Pathogenesis of diabetic nephropathy: the role of oxidative stress and kinase C. Diabetes Res Clin Pract 45:147–151PubMedCrossRefGoogle Scholar
  27. Ha H, Lee HB (2000) Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 58(Suppl 77):S-19–S-25Google Scholar
  28. Ha H, Yu MR, Choi YJ, Lee HB (2001) Activation of protein kinase C-δ and C-ε by oxidative stress in early diabetic rat kidney. Am J Kidney Dis 38:S204–S207PubMedCrossRefGoogle Scholar
  29. Ha H, Yu MR, Kim KH (1999) Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 26:944–950PubMedCrossRefGoogle Scholar
  30. Haber CA, Lam TK, Yu Z, Gupta N, Goh T, Bogdanovic E, Giacca A, Fantus IG (2003) N-Acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab 285:E744–E753PubMedGoogle Scholar
  31. Hansen SH (2001) The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 17:330–346PubMedCrossRefGoogle Scholar
  32. Hebden RA, Gardiner SM, Bennett T, MacDonald IA (1986) The influence of streptozotocin-induced diabetes mellitus on fluid and electrolyte handling in rats. Clin Sci (Lond) 70:111–117Google Scholar
  33. Higo S, Miyata S, Jiang QY, Kitazawa R, Kitazawa S, Kasuga M (2008) Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats. Kobe J Med Sci 54:E35–E45PubMedGoogle Scholar
  34. Hissin PJ, Hilf R (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214–226PubMedCrossRefGoogle Scholar
  35. Huang JS, Chuang LY, Guh JY, Huang YJ, Hsu MS (2007) Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol 293:F1072–F1082CrossRefGoogle Scholar
  36. Huang JS, Chuang LY, Guh JY, Yang YL, Hsu MS (2008) Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells. Toxicol Appl Pharmacol 233:220–226PubMedCrossRefGoogle Scholar
  37. Jiang QY (2002) Mechanisms of beneficial effects of taurine on diabetic nephropathy. Med J Kobe Univ 62:119–126Google Scholar
  38. Joyner JL, Peyer SM, Lee RW (2003) Possible roles of sulfur-containing amino acids in a chemoautotrophic bacterium-mollusc symbiosis. Biol Bull 205:331–338PubMedCrossRefGoogle Scholar
  39. Kaplan B, Karabay G, Zağyapan RD, Ozer C, Sayan H, Duyar I (2004) Effects of taurine in glucose and taurine administration. Amino Acids 27:327–333PubMedCrossRefGoogle Scholar
  40. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS (2010) Oxidative stress in diabetic nephropathy. Curr Med Chem 17:4256–4269PubMedCrossRefGoogle Scholar
  41. Katsumata M, Kiuchi K, Tashiro T, Uchikuga S (1997) Methods for scavenging active oxygen compounds and preventing damage from ultra violet B rays using taurine analogues. US Patent Number 5:601,806Google Scholar
  42. Kono Y (1998) New raw materials and new technologies for cosmetics. (Part I). Development and its application of “sebum antioxidant thiotaurine” for cosmetics. Fragr J 26:9–14Google Scholar
  43. Kono Y, Miyaji Y (2000) Peroxidation in the skin and its prevention. Jpn J Inflamm 20:119–129Google Scholar
  44. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M (2003) Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 14:S250–S253PubMedCrossRefGoogle Scholar
  45. Kulakowski EC, Maturo J (1984) Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol 33:2835–2838PubMedCrossRefGoogle Scholar
  46. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB (2005) Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 67:1762–1771PubMedCrossRefGoogle Scholar
  47. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling ­pathways in diabetic nephropathy. J Am Soc Nephrol 14:S241–S245PubMedCrossRefGoogle Scholar
  48. Li F, Obrosova IG, Abatan O, Tian D, Larkin D, Stuenkel EL, Stevens MJ (2004) Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats. Am J Physiol Endocrinol Metab 288:E29–E36CrossRefGoogle Scholar
  49. Mathiesen ER, Hommel E, Giese J, Parving HH (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 303:81–87CrossRefGoogle Scholar
  50. Miller JA (1999) Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10:1778–1785PubMedGoogle Scholar
  51. Monnier L, Colette C (2008) Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. Expert Opin Pharmacother 9:2857–2865PubMedCrossRefGoogle Scholar
  52. Naito Y, Uchiyama K, Aoi W, Hasegawa G, Nakamura N, Yoshida N, Maoka T, Takahashi J, Yoshikawa T (2004) Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors 20:49–59PubMedCrossRefGoogle Scholar
  53. Nandhini AT, Thirunavukkarasu V, Anuradha CV (2004) Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol Scand 181:297–303PubMedCrossRefGoogle Scholar
  54. Obrosova IG (2005) Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7:1543–1552PubMedCrossRefGoogle Scholar
  55. Obrosova IG, Stevens MJ (1999) Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest Ophthalmol Vis Sci 40:680–688PubMedGoogle Scholar
  56. Odetti P, Pesce C, Traverso N, Menini S, Maineri EP, Cosso L, Valentini S, Patriarca S, Cottalasso D, Marinari UM, Pronzato MA (2003) Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes. Diabetes 52:499–505PubMedCrossRefGoogle Scholar
  57. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R (2007) Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18:2945–2952PubMedCrossRefGoogle Scholar
  58. Pruski AM, Fiala-Médioni A (2003) Stimulatory effect of sulphide on thiotaurine synthesis in three hydrothermal-vent species from the East Pacific Rise. J Exp Biol 206:2923–2930PubMedCrossRefGoogle Scholar
  59. Reckelhoff JF, Tygart VL, Mitias MM, Walcott JL (1993) STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42:1425–1432PubMedCrossRefGoogle Scholar
  60. Ribeiro RA, Bonfleur ML, Amaral AG, Vanzela EC, Rocco SA, Boschero AC, Carneiro EM (2009) Taurine supplementation enhances nutrient-induced insulin secretion in pancreatic mice islets. Diabetes Metab Res Rev 25:370–379PubMedCrossRefGoogle Scholar
  61. Rossing K, Christensen PK, Jensen BR, Parving HH (2002a) Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25:95–100PubMedCrossRefGoogle Scholar
  62. Rossing P, Hougaard P, Parving HH (2002b) Risk factors for development of incipient and diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 25:859–864PubMedCrossRefGoogle Scholar
  63. Schaffer SW, Azuma J, Mozaffari M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87:91–99PubMedCrossRefGoogle Scholar
  64. Simşek M, Naziroğlu M, Erdinç A (2005) Moderate exercise with a dietary vitamin C and E combination protects against streptozotocin-induced oxidative damage to the kidney and lens in pregnant rats. Exp Clin Endocrinol Diabetes 113:53–59PubMedCrossRefGoogle Scholar
  65. Tada H, Ishii H, Isogai S (1997) Protective effect of D-alpha-tocopherol on the function of human mesangial cells exposed to high glucose concentrations. Metabolism 46:779–784PubMedCrossRefGoogle Scholar
  66. Trachtman H, Futterweit S, Bienkowski R (1993) Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells. Biochem Biophys Res Commun 191:759–765PubMedCrossRefGoogle Scholar
  67. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A, Tarectecan AA, Rao PS, Sturman JA, Boles TH (1995) Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol 269:F429–F438PubMedGoogle Scholar
  68. Trachtman H, Futterweit S, Prenner J, Hanon S (1994) Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun 199:346–352PubMedCrossRefGoogle Scholar
  69. Vaishya R, Singh J, Lal H (2009) Biochemical effects of irbesartan in experimental diabetic nephropathy. Indian J Pharmacol 41:252–254PubMedCrossRefGoogle Scholar
  70. Verzola D, Bertolotto MB, Villaggio B, Ottonello L, Dallegri F, Frumento G, Berruti V, Gandolfo MT, Garibotto G, Deferran G (2002) Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J Investig Med 50:443–451PubMedCrossRefGoogle Scholar
  71. Wang LJ, Zhang L, Yu Y, Wang Y, Niu N (2008) The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression. Ren Fail 30:763–771PubMedCrossRefGoogle Scholar
  72. Winiarska K, Szymanski K, Gorniak P, Dudziak M, Bryla J (2008) Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 91:261–270PubMedCrossRefGoogle Scholar
  73. Wollenberger A, Ristau O, Schoffa G (1960) Eine einfache Technik der extrem schneller Abkühlung grösserer Gewebstücke. Pflügers Arch. Gesamte Physiol. Menschen Tiere 270:399–412PubMedCrossRefGoogle Scholar
  74. Yancey PH (2005) Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol 208:2819–2830PubMedCrossRefGoogle Scholar
  75. Yancey PH, Ishikawa J, Meyer B, Girguis PR, Lee RW (2009) Thiotaurine and hypotaurine contents in hydrothermal-vent polychaetes without thiotrophic endosymbionts: correlation with sulfide exposure. J Exp Zool A Ecol Genet Physiol 311A:439–447CrossRefGoogle Scholar
  76. Yao HT, Lin P, Chang YW, Chen CT, Chiang MT, Chang L, Kuo YC, Tsai HT, Yeh TK (2009) Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes. Food Chem Toxicol 47:1703–1709PubMedCrossRefGoogle Scholar
  77. Yoshiyuki K, Yoshiki M (2000) Peroxidation in the skin and its prevention. Jpn J Inflamm 20:119–129PubMedCrossRefGoogle Scholar
  78. Zheng CM, Ma WY, Wu CC, Lu KC (2012) Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta 413:1555–1561PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kashyap G. Pandya
    • 1
  • Roshil Budhram
    • 1
  • George Clark
    • 1
  • Cesar A. Lau-Cam
    • 1
    Email author
  1. 1.Department of Pharmaceutical SciencesSt. John’s University, College of Pharmacy and Health Professions, JamaicaNew YorkUSA

Personalised recommendations